Medicine Status

Bulevirtide – July 2025

Bulevirtide; Powder for injection 2 mg; Hepcludex® – March 2025 – July 2025

Brand names:
- Hepcludex®
Pharmaceutical Company:
- GILEAD SCIENCES PTY LTD
Condition/Indication: Chronic hepatitis D
Meeting Date: July 2025
Public Summary Document (PSD) March 2025 July 2025 March 2026 Meetings - (PDF)
Public Summary Document (PSD) March 2025 July 2025 March 2026 Meetings - (DOCX)

Last updated

9 July 2025